^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Small Cell Lung Cancer
    Drug:Tyvyt (sintilimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase II Study for Maintenance IBI308 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).

    Excerpt:
    ...The positive expression of PD-L1 (PD-L1 > 1 SP142PD-L1 immunocytochemical antibody) was detected by IHC in the local laboratory using previously archived or freshly obtained tumor tissues or biopsy specimens; 7. ...
    Trial ID:
    ChiCTR1800018861
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

    Excerpt:
    ...Participant need to provided tumor tissue (from an archival tumor sample obtained within 1 year or from a new biopsy sample) for PD-L1 immunohistochemical (IHC) assay, and PD-L1expression in more than 1% cells is required; 8....
    Trial ID:
    NCT03994744
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    IASLC-WCLC 2020
    Title:

    P48.15 - A Case from a Single-Arm, Phase Two, Open Label Study Assessing Sindilimab Plus Metaformin in Chemotherapy Failed PD-L1 Positive Advanced SCLC

    Published date:
    01/12/2021
    Excerpt:
    ...SCLC patients were positive for PD-L1 expression, only two patients met the inclusion criteria and received Sindilimab and metaformin (S+M) treatment. One of these two patient (P004) showed favorable response....The combination of Sindilimab plus metaformin showed potential efficacy on second line treatment in this PD-L1 positive SCLC case…
    Secondary therapy:
    metformin
    Trial ID:
    NCT03994744